U.S. drug regulators will decide whether to greenlight booster doses of Pfizer’s COVID-19 vaccine for all Americans 16 or older without convening its expert vaccine advisory panel, the Food and Drug Administration (FDA) confirmed to The Epoch Times on Wednesday. FDA’s acting head and other top Biden administration officials said earlier this year that booster doses should be given to all because of waning vaccine efficacy against the virus that causes COVID-19. But the advisory panel recommended boosters only for certain groups, arguing the data did not support widespread second and third doses. That panel, though, won’t get a chance to weigh in as regulators consider Pfizer’s Nov. 9 request. “The FDA does not plan to hold a meeting of the Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Pfizer’s request to amend their emergency use authorization to include the use of a single booster dose for all individuals …